Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial
European Journal of Heart Failure · 2025
DOI: 10.1002/ejhf.70026 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift European Journal of Heart Failure, 2025. Verfasst von Luis Eduardo Echeverria und 27 weiteren Autor:innen. Beteiligte Einrichtung: Fundación Cardiovascular de Colombia, Universidad de Santander, Floridablanca, Colombia. Hauptthemen laut MEDLINE: Aminobutyrates, Heart Failure, Enalapril, Chagas Cardiomyopathy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Novartis It is a Novartis Sponsored Study, Novartis.
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Aims
The PARACHUTE-HF trial (NCT04023227) is evaluating the effect of sacubitril/valsartan compared with enalapril on a hierarchical composite of cardiovascular events (cardiovascular death, first heart failure hospitalization), and change in N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels in participants with heart failure and reduced ejection fraction (HFrEF) caused by chronic Chagas cardiomyopathy (CCC). We describe the baseline characteristics of participants in PARACHUTE-HF compared with prior HFrEF trials. Methods and results PARACHUTE-HF, a multicentre, active-controlled, open-label trial, enrolled 922 participants with confirmed CCC, New York Heart Association (NYHA) functional class II–IV, and left ventricular ejection fraction (LVEF) ≤40%. Participants were randomized 1:1 to sacubitril/valsartan (97/103 mg bid) or enalapril (10 mg bid). Enrolled participants (mean age: 64.2 years, 42.0% women) had a baseline LVEF of 29.8% (NYHA class II: 61.7%; NHYA class III/IV: 38.2%). History included hypertension (40.5%), atrial fibrillation/flutter (32.5%), ventricular arrhythmia (24.7%) and stroke (12.5%). The majority of patients had cardiac conduction abnormalities and 46.0% had conventional pacemaker, cardiac resynchronization therapy or implantable cardioverter-defibrillator. Mean systolic blood pressure was 118 mmHg, and median NT-proBNP level was 1730 pg/ml.
Conclusions
Baseline characteristics of this study highlight the unique clinical profile of patients with CCC-related HFrEF, including the high proportion of women affected, lower rates of comorbidities (hypertension/diabetes) and higher prevalence of stroke and pacemaker implantation when compared with other non-CCC-related HFrEF studies. These findings reinforce the need for dedicated heart failure treatments in this neglected subpopulation, particularly in Latin America where Chagas disease remains a significant public health issue.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fundación Cardiovascular de Colombia, Universidad de Santander, Floridablanca, Colombia.
- Heart Failure Clinics, Instituto do Coração (InCor), Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil.
- Novartis Pharma AG, Basel, Switzerland.
- Brazilian Clinical Research Institute (BCRI), São Paulo, Brazil.
- Libin Cardiovascular Institute, University of Calgary, Calgary, AB, Canada.
- Hospial D.F. Santojanni, Buenos Aires University, Buenos Aires, Argentina.
ORCID-Profile: Caroline Demacq, Renato Delascio Lopes
Förderung
- Novartis It is a Novartis Sponsored Study
- Novartis
Zitieren
APA
Echeverria, L. E., Bocchi, E., Demacq, C., de Barros E Silva, P. G. M., Chiang, L. M., Sayyed, S., Damiani, L. P., Barbosa, L. M., Furtado, R. H. M., Morillo, C. A., Kevorkian, R., Ramires, F., Bahit, M. C., Chavez-Mendoza, A., Magaña-Serrano, J. A., Carbajales, J., Oliveira Junior, W., Molina, I., Freitas Junior, A. F., …, & on behalf of the PARACHUTE‐HF Investigators (2025). Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.70026
Vancouver
Echeverria LE, Bocchi E, Demacq C, de Barros E Silva PGM, Chiang LM, Sayyed S, et al. Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial. European Journal of Heart Failure. 2025. doi:10.1002/ejhf.70026
BibTeX
@article{Echeverria2025,
author = {Echeverria, Luis Eduardo and Bocchi, Edimar and Demacq, Caroline and de Barros E Silva, Pedro Gabriel Melo and Chiang, Lu-May and Sayyed, Sarfaraz and Damiani, Lucas Petri and Barbosa, Lilian Mazza and Furtado, Remo Holanda de Mendonça and Morillo, Carlos A and Kevorkian, Ruben and Ramires, Felix and Bahit, Maria Cecilia and Chavez-Mendoza, Adolfo and Magaña-Serrano, José Antonio and Carbajales, Justo and Oliveira Junior, Wilson and Molina, Israel and Freitas Junior, Aguinaldo F and Moreira, Maria da Consolaçao and Silva, Adegil Henrique and Silva Junior, Telemaco and Saporito, Wladimir and Kerr Saraiva, José Francisco and Gimpelewicz, Claudio and McMurray, John J V and Lopes, Renato Delascio and on behalf of the PARACHUTE‐HF Investigators, on behalf of the PARACHUTE‐HF Investigators},
title = {Sacubitril/Valsartan Versus Enalapril in Chronic Chagas Cardiomyopathy with Heart Failure: Baseline Characteristics of the PARACHUTE-HF Trial},
journal = {European Journal of Heart Failure},
year = {2025},
doi = {10.1002/ejhf.70026}
}
EUVIMED